Rhythm Pharmaceuticals, Inc. (NASDAQ:RYTM) was founded in February 2013, with a history dating back to November 2008, formerly known as Rhythm Metabolic, Inc., changed to its current name in October 2015, and headquartered in Massachusetts, USA Boston, with 15 full-time employees (9/25/2017), is a clinical-stage biopharmaceutical company focusing on the development and commercialization of peptide therapeutics for the treatment of rare genetic defects that lead to life-threatening metabolic disorders.
Rhythm Pharmaceuticals (RYTM):
Rhythm Pharmaceuticals’ main peptide product candidate, setmelanotide, is an effective melanocortin-4 receptor (MC4R, melanocortin-4 receptor) agonist for the treatment of rare genetic diseases of obesity. The company believes that setmelanotide (Rhythm Pharmaceuticals has global rights) may be used as an alternative therapy to treat melanocortin 4 or MC4 pathway defects. The MC4 pathway is an attractive target for the treatment of these genetic diseases because it plays a key role in regulating appetite and weight, and peptide therapeutics are uniquely suited to activate this target.
Currently, Rhythm Pharmaceuticals is evaluating setmelanotide for the treatment of six genetic obesity diseases, including: pro-opiomelanocortin (POMC), leptin receptor (LEPR) deficiency obesity, Prader-Willi syndrome (PWS), Bardet-Biedl syndrome , Alström syndrome and POMC heterozygosity defect obesity.
Rhythm Pharmaceuticals (RYTM) investment:
Rhythm Pharmaceuticals, Inc. (NASDAQ:RYTM) submitted its IPO prospectus on 9/5/2017 and listed on NASDAQ on 10/5/2017. The issue price was US$17.00, 6,666,666 shares were issued, and the fundraising was $122,666,656.00. The stock code: RYTM.